Fixed-combination therapy to improve blood pressure control: experience with olmesartan-based therapy

Related Experiment Video

Updated: May 30, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Giuliano Tocci1, Massimo Volpe

  • 1Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome Sapienza, Sant'Andrea Hospital, Via di Grottarossa 1035-9, 00189 Rome, Italy.

Expert Review of Cardiovascular Therapy
|August 4, 2011
PubMed

Insights

Effective hypertension management is crucial for reducing cardiovascular disease. Combination therapies, particularly those involving renin-angiotensin system inhibitors and olmesartan medoxomil, offer improved blood pressure control and tolerability.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Hypertension is a global health challenge with suboptimal control rates worldwide.
  • Even with treatment, hypertensive patients often face elevated cardiovascular risk due to comorbidities.
  • Monotherapy may be insufficient for achieving optimal blood pressure control in many patients.

Purpose of the Study:

  • To review fixed-combination antihypertensive strategies.
  • To highlight the efficacy and safety of combinations involving renin-angiotensin system inhibitors.
  • To focus on fixed-combination strategies utilizing olmesartan medoxomil.

Main Methods:

  • Review of current clinical practice guidelines and pharmacological data.
  • Analysis of combination therapies involving renin-angiotensin system inhibitors, thiazide diuretics, and calcium channel-blockers.
  • Examination of fixed-combination products, specifically olmesartan medoxomil-based formulations.

Main Results:

  • Combination therapy demonstrates superior blood pressure lowering compared to monotherapy.
  • Fixed combinations of renin-angiotensin system inhibitors with thiazide diuretics or calcium channel-blockers are effective and well-tolerated.
  • Olmesartan medoxomil-based fixed combinations offer a valuable therapeutic option for hypertension management.

Conclusions:

  • Fixed-combination antihypertensive therapy is an effective strategy for improving blood pressure control.
  • Olmesartan medoxomil-based fixed combinations represent a significant advancement in managing hypertension and reducing cardiovascular risk.
  • Wider adoption of combination therapies, including fixed-dose formulations, is recommended for better patient outcomes.

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...